Show simple item record

dc.contributor.authorDean, Emma J
dc.contributor.authorRanson, Malcolm R
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorHolt, Sarah V
dc.contributor.authorDive, Caroline
dc.date.accessioned2009-07-07T16:21:06Z
dc.date.available2009-07-07T16:21:06Z
dc.date.issued2007-04
dc.identifier.citationNovel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic. 2007, 33 (2):203-12 Cancer Treat. Rev.en
dc.identifier.issn0305-7372
dc.identifier.pmid17210228
dc.identifier.doi10.1016/j.ctrv.2006.11.002
dc.identifier.urihttp://hdl.handle.net/10541/72880
dc.description.abstractLung cancer is the leading cause of cancer death worldwide. Despite the introduction of new agents and schedules, chemotherapy still obtains unsatisfactory overall response rates, rare complete remissions and responses of relatively short duration. The inhibitor of apoptosis proteins (IAPS) are a family of caspase inhibitors that selectively bind and inhibit caspases-3, -7, and -9. As caspase activation is central to apoptosis, novel therapeutic drugs that target IAPs enabling apoptosis to occur have potential as a treatment of malignancy. Several agents that target core components of the apoptotic signalling pathway are currently at an early stage of development. This review reports the progress being made in characterising the IAP family, with a focus on the available data relevant to the treatment of lung cancer.
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshApoptosis
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshCarcinoma, Small Cell
dc.subject.meshCaspases
dc.subject.meshHumans
dc.subject.meshInhibitor of Apoptosis Proteins
dc.subject.meshLung Neoplasms
dc.titleNovel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, United Kingdom. emma.dean@christie-tr.nwest.nhs.uk <emma.dean@christie-tr.nwest.nhs.uk>en
dc.identifier.journalCancer Treatment Reviewsen
html.description.abstractLung cancer is the leading cause of cancer death worldwide. Despite the introduction of new agents and schedules, chemotherapy still obtains unsatisfactory overall response rates, rare complete remissions and responses of relatively short duration. The inhibitor of apoptosis proteins (IAPS) are a family of caspase inhibitors that selectively bind and inhibit caspases-3, -7, and -9. As caspase activation is central to apoptosis, novel therapeutic drugs that target IAPs enabling apoptosis to occur have potential as a treatment of malignancy. Several agents that target core components of the apoptotic signalling pathway are currently at an early stage of development. This review reports the progress being made in characterising the IAP family, with a focus on the available data relevant to the treatment of lung cancer.


Files in this item

This item appears in the following Collection(s)

Show simple item record